LivaNova PLC

Valuation Analysis

About the Company

LivaNova PLC en bref

LivaNova PLC (LIVN) is currently trading at 68,43 € with a market capitalization of 3,8 Md €. The trailing P/E ratio stands at 40.05x, with a forward P/E of 16.95x. The 52-week range spans from 35,76 € to 70,57 €; the current price is 3% below the yearly high. Year-over-year revenue growth stands at +14.3%. The net profit margin stands at 7.47%.

💰 Dividende

LivaNova PLC currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

10 analystes évaluent LivaNova PLC (LIVN) au consensus : Acheter. L'objectif de cours moyen est de 70,26 €, soit un potentiel de +2.68% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 58,41 € à 82,82 €.

LivaNova PLC : la thèse d'investissement en détail

LivaNova PLC (LIVN) operates in the Healthcare — specifically Medical Devices — and is headquartered in United Kingdom. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 14.3% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 67.86%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

Le scénario baissier

Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

With a PEG ratio of 0.91, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

À surveiller

• The forward P/E of 16.95x is meaningfully below the trailing 40.05x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 93.9% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (6.99%).

Trading Data

Related Stocks in the Same Sector

Where can I buy LivaNova PLC?

Compare top-rated brokers — low fees, trusted providers, fully regulated.